Second time not the charm; Angioplasty touted as alternative to tPA
Second time not the charm
Gensia Pharmaceutical Inc.'s presentation at the American College of Cardiology meeting of Phase III data on Arasine in coronary artery bypass surgery failed to reassure investors, who pushed the stock down 30 percent last week to $16..
The stock had been languishing in the 20s since unhappy investors sold off shares after the first look at the data in September.
Most confusing in last week's presentation, according to analysts, was the fact